One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

The Roundup covers notable class action decisions from federal appellate courts and notable Supreme Court class action cert petitions.

Boehringer Ingelheim, Eli Lilly, Moonlake Immunotherapeutics, and Aristea Therapeutics. Sabyasachi Ghosh (Associate Vice ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Boehringer Ingelheim & WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention: Ingelheim, Germany Wednesday, October 16, ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...